OPTHEA LTD-SPON ADR (OPT) Stock Price, Forecast & Analysis
NASDAQ:OPT • US68386J2087
OPT Key Statistics, Chart & Performance
The current stock price of OPT is 3.41 USD. In the past month the price decreased by -34.55%. In the past year, price decreased by -1.16%.
OPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OPT. When comparing the yearly performance of all stocks, OPT turns out to be only a medium performer in the overall market: it outperformed 59.46% of all stocks.
OPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPT. Both the profitability and financial health of OPT have multiple concerns.
OPT Financial Highlights
Over the last trailing twelve months OPT reported a non-GAAP Earnings per Share(EPS) of -2. The EPS increased by 16.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OPT Forecast & Estimates
10 analysts have analysed OPT and the average price target is 6.57 USD. This implies a price increase of 92.75% is expected in the next year compared to the current price of 3.41.
For the next year, analysts expect an EPS growth of 56.03% and a revenue growth -37% for OPT
OPT Ownership
OPT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OPT
Company Profile
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Company Info
OPTHEA LTD-SPON ADR
Suite 0403, Level 4, 650 Chapel Street, South Yarra
Melbourne VICTORIA 3141 AU
CEO: Megan Baldwin
Employees: 33
Phone: 61398260399
OPTHEA LTD-SPON ADR / OPT FAQ
Can you describe the business of OPTHEA LTD-SPON ADR?
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Can you provide the latest stock price for OPTHEA LTD-SPON ADR?
The current stock price of OPT is 3.41 USD. The price increased by 7.23% in the last trading session.
Does OPTHEA LTD-SPON ADR pay dividends?
OPT does not pay a dividend.
What is the ChartMill rating of OPTHEA LTD-SPON ADR stock?
OPT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for OPT stock?
The Revenue of OPTHEA LTD-SPON ADR (OPT) is expected to decline by -37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for OPTHEA LTD-SPON ADR?
OPTHEA LTD-SPON ADR (OPT) has a market capitalization of 524.75M USD. This makes OPT a Small Cap stock.